The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...

Ribometrix, a spinout of UNC-Chapel Hill, has named William Marshall as its new CEO, succeeding former chief executive ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

Amgen Inc. closed $79.75 short of its 52-week high ($346.85), which the company achieved on July 25th.

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Amgen (AMGN) stock in focus as U.S. approval for its lung cancer drug expands for metastatic colorectal cancer. Read more ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...